Cardiol Therapeutics Inc
Cardiol Therapeutics Inc (CRDL) Historical Volatility
CRDL's 30 day historical volatility is 55.90%, in the 41st percentile of readings over the past year. This is an average percentile, meaning Cardiol Therapeutics Inc shares have moved roughly in line with their typical range. CRDL's 30 day implied volatility sits at 9,193.53%, with an IV Rank of 99.60%, leaving IV 9,137.63 points above historical volatility. This means options are pricing in more movement than the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking CRDL historical volatility helps you see how much Cardiol Therapeutics Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, CRDL's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor CRDL 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. CRDL's 30 day historical volatility, or CRDL HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing CRDL's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx as a cardioprotective therapy to reduce cardiovascular and respiratory events in patients hospitalized with COVID-19, as well as to evaluate the efficacy and safety of CardiolRx in acute myocarditis. The company is also developing subcutaneous formulation of CardiolRx for the treatment of fibrosis and inflammation in the heart that is related with the development and progression of heart failure.
Historical Volatility
Historical movement is near its typical level for the past year. Neither unusually calm nor unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →